CVA Family Office’s ADMA Biologics ADMA Stock Holding History

CVA Family Office’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-71	Closed	-$640	–	1804
2026 Q1	$640	Buy	+71	New	+$1.12K	﹤0.01%	1717

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CVA Family Office's ADMA Position: Q2 2026 in Review

CVA Family Office sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 71 shares — an estimated $640 sold.

CVA Family Office first reported a position in ADMA in Q1 2026 and held it in 1 quarter. The position peaked at $640 in Q1 2026. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

CVA Family Office reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
CVA Family Office sold 71 ADMA Biologics shares in Q2 2026, an estimated $640.
CVA Family Office first reported a position in ADMA Biologics in Q1 2026 and held it in 1 quarter.
CVA Family Office's ADMA Biologics position peaked at $640 in Q1 2026.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.